American Thoracic Society, 2024
Efzofitimod Promotes Macrophages with Anti-inflammatory Profile via Neuropilin-2 Receptor
Keystone Symposia: Myeloid Cell Diversity, 2024
Efzofitimod, a First-in-Class NRP2-Targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
American College of Rheumatology, 2023
Exposure-Response Analyses of Efzofitimod in Patients With Pulmonary Sarcoidosis
Frontiers in Pharmacology, 2023
Therapeutic Doses of Efzofitimod Significantly Improve Multiple Pulmonary Sarcoidosis Efficacy Measures
European Respiratory Society, 2023
Efzofitimod: A Novel Therapeutic Candidate for SSc-ILD
European Respiratory Society, 2023
EFZO-FIT™: A Phase 3 Study of Efzofitimod, a Novel Immunomodulator for the Treatment of Pulmonary Sarcoidosis
World Association for Sarcoidosis and Other Granulomatous Disorders, 2023
Exposure-Efficacy Analysis Supports Proof of Concept for Efzofitimod in Pulmonary Sarcoidosis
American Thoracic Society, 2023
Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells
American Thoracic Society, 2023
Efzofitimod: A Novel Anti-Inflammatory Agent for Sarcoidosis
Baughman RP, Niranjan V, Walker G, Burkart C, Paz S, Chong YE, Siefker D, Sun E, Nangle L, Förster S, Muders MH, Farver CF, Lower EE, Shukla S, Culver DA.
Sarcoidosis, Vasculitis and Diffuse Lung Diseases (2023)